Curcumin loaded solid lipid nanoparticles ameliorate adjuvant-induced arthritis in rats

European Journal of Pain (United Kingdom)

Volumn 19, Issue 7, 2015, Pages 940-952

  Arora, R ^a   Kuhad, A ^a   Kaur, I P ^a   Chopra, Kanwaljit ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CURCUMIN; CURCUMIN LOADED SOLID LIPID NANOPARTICLE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; FREUND ADJUVANT; NAPROXEN; PROTECTIVE AGENT; SOLID LIPID NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; LIPOSOME; NANOPARTICLE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG SYNTHESIS; HYPERALGESIA; INVESTIGATIVE PROCEDURES; JOINT HYPERALGESIA; JOINT STIFFNESS; LEUKOCYTE COUNT; MALE; NITROSATIVE STRESS; NONHUMAN; PRIORITY JOURNAL; RANDALL-SELITTO TEST; RAT; REACTION TIME; THERMAL HYPERALGESIA; VON FREY TEST; ANIMAL; ARTHRITIS, EXPERIMENTAL; DOSE RESPONSE; DRUG EFFECTS; JOINT; LIPID PEROXIDATION; METABOLISM; OXIDATIVE STRESS; PAIN MEASUREMENT; PATHOLOGY; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; CURCUMIN; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FREUND'S ADJUVANT; HYPERALGESIA; JOINTS; LIPID PEROXIDATION; LIPOSOMES; MALE; NANOPARTICLES; OXIDATIVE STRESS; PAIN MEASUREMENT; RATS; RATS, WISTAR;

EID: 84947018527     PISSN: 10903801     EISSN: 15322149     Source Type: Journal    
DOI: 10.1002/ejp.620     Document Type: Article

References (41)

1. Aggarwal, B.B., Harikumar, K.B., (2009). Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 41, 40-59.
2. Anand, P., Thomas, S.G., Kunnumakkara, A.B., Sundaram, C., Harikumar, K.B., Sung, B., Tharakan, S.T., Misra, K., Priyadarsini, I.K., Rajasekharan, K.N., Aggarwal, B.B., (2008). Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 76, 1590-1611.
3. Banerjee, M., Tripathi, L.M., Srivastava, V.M., Puri, A., Shukla, R., (2003). Modulation of inflammatory mediators by ibuprofen and curcumin treatment during chronic inflammation in rat. Immunopharmacol Immunotoxicol 25, 213-224.
4. Bongartz, T., Sutton, A.J., Sweeting, M.J., Buchan, I., Matteson, E.L., Montori, V., (2006). Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275-2285.
5. Butler, S.H., Godefroy, F., Besson, J.M., Weil-Fugazza, J., (1992). A limited arthritic model for chronic pain studies in the rat. Pain 48, 73-81.
6. Chaplan, S.R., Bach, F.W., Pogrel, J.W., Chung, J.M., Yaksh, T.L., (1994). Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53, 55-63.
7. Clairborne, A., (1985). Catalase activity. In Handbook of Methods for Oxygen Radical Research, R.A. Greenwald, ed. (Boca Raton, FL: CRC Press) pp. 283-284.
8. Feist, E., Burmester, G.R., (2009). Is tocilizumab in combination with traditional DMARDs safe and effective for patients with active RA? Nat Clin Pract Rheumatol 5, 128-129.
9. Filippin, L.I., Vercelino, R., Marroni, N.P., Xavier, R.M., (2008). Redox signalling and the inflammatory response in rheumatoid arthritis. Clin Exp Immunol 152, 415-422.
10. Green, L.C., Wagner, D.A., Glogowski, J., Skipper, P.L., Wishnok, J.S., Tannenbaum, S.R., (1982). Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 126, 131-138.
11. Haugeberg, G., Orstavik, R.E., Uhlig, T., Falch, J.A., Halse, J.I., Kvien, T.K., (2002). Bone loss in patients with rheumatoid arthritis: Results from a population-based cohort of 366 patients followed up for two years. Arthritis Rheum 46, 1720-1728.
12. Hill, J.A., Southwood, S., Sette, A., Jevnikar, A.M., Bell, D.A., Cairns, E., (2003). Cutting edge: The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1∗0401 MHC class II molecule. J Immunol 171, 538-541.
13. Holt, P.R., Katz, S., Kirshoff, R., (2005). Curcumin therapy in inflammatory bowel disease: A pilot study. Dig Dis Sci 50, 2191-2193.
14. Jollow, D.J., Mitchell, J.R., Zampaglione, N., Gillette, J.R., (1974). Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology 11, 151-169.
15. Kageyama, Y., Takahashi, M., Ichikawa, T., Torikai, E., Nagano, A., (2008). Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Clin Exp Rheumatol 26, 73-80.
16. Kakkar, V., Mishra, A.K., Chuttani, K., Kaur, I.P., (2013a). Proof of concept studies to confirm the delivery of curcumin loaded solid lipid nanoparticles (C-SLNs) to brain. Int J Pharm 448, 354-359.
17. Kakkar, V., Muppu, S.K., Chopra, K., Kaur, I.P., (2013b). Curcumin loaded solid lipid nanoparticles: An efficient formulation approach for cerebral ischemic reperfusion injury in rats. Eur J Pharm Biopharm 85, 339-345.
18. Kakkar, V., Singh, S., Singla, D., Kaur, I.P., (2011). Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol Nutr Food Res 55, 495-503.
19. Kaur, I.P., Bhandari, R., Bhandari, S., Kakkar, V., (2008). Potential of solid lipid nanoparticles in brain targeting. J Control Release 127, 97-109.
20. Kono, Y., (1978). Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase. Arch Biochem Biophys 186, 189-195.
21. Kurien, B.T., Scofield, R.H., (2008). Autoimmunity and oxidatively modified autoantigens. Autoimmun Rev 7, 567-573.
22. Lee, D.M., Weinblatt, M.E., (2001). Rheumatoid arthritis. Lancet 358, 903-911.
23. Li, M., Wang, L., Liu, H., Su, B., Liu, B., Lin, W., Li, Z., Chang, L., (2013). Curcumin inhibits HeLa cell invasion and migration by decreasing inducible nitric oxide synthase. Nan Fang Yi Ke Da Xue Xue Bao 33, 1752-1756.
24. Luo, Y., Chen, D., Ren, L., Zhao, X., Qin, J., (2006). Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release 114, 53-59.
25. Masson-Bessiere, C., Sebbag, M., Durieux, J.J., Nogueira, L., Vincent, C., Girbal-Neuhauser, E., Durroux, R., Cantagrel, A., Serre, G., (2000). In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol 119, 544-552.
26. Nagakura, Y., Okada, M., Kohara, A., Kiso, T., Toya, T., Iwai, A., Wanibuchi, F., Yamaguchi, T., (2003). Allodynia and hyperalgesia in adjuvant-induced arthritic rats: Time course of progression and efficacy of analgesics. J Pharmacol Exp Ther 306, 490-497.
27. Nakashima, K., Hagiwara, T., Yamada, M., (2002). Nuclear localization of peptidylarginine deiminase V and histone deimination in granulocytes. J Biol Chem 277, 49562-49568.
28. Nielen, M.M., van Schaardenburg, D., Reesink, H.W., Twisk, J.W., van de Stadt, R.J., van der Horst-Bruinsma, I.E., de Gast, T., Habibuw, M.R., Vandenbroucke, J.P., Dijkmans, B.A., (2004). Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum 50, 2423-2427.
29. Pepys, M.B., Baltz, M.L., (1983). Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 34, 141-212.
30. Rupniak, N.M., Boyce, S., Webb, J.K., Williams, A.R., Carlson, E.J., Hill, R.G., Borkowski, J.A., Hess, J.F., (1997). Effects of the bradykinin B1 receptor antagonist des-Arg9[Leu8]bradykinin and genetic disruption of the B2 receptor on nociception in rats and mice. Pain 71, 89-97.
31. Saxne, T., Palladino, M.A. Jr., Heinegard, D., Talal, N., Wollheim, F.A., (1988). Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 31, 1041-1045.
32. Scott, D.L., Pugner, K., Kaarela, K., Doyle, D.V., Woolf, A., Holmes, J., Hieke, K., (2000). The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 39, 122-132.
33. Stewart, A., Mackenzie, L.M., Black, A.J., Reid, D.M., (2004). Predicting erosive disease in rheumatoid arthritis. A longitudinal study of changes in bone density using digital X-ray radiogrammetry: A pilot study. Rheumatology (Oxford) 43, 1561-1564.
34. Streetz, K.L., Wustefeld, T., Klein, C., Manns, M.P., Trautwein, C., (2001). Mediators of inflammation and acute phase response in the liver. Cell Mol Biol (Noisy-Le-Grand) 47, 661-673.
35. Sukkar, S.G., Rossi, E., (2004). Oxidative stress and nutritional prevention in autoimmune rheumatic diseases. Autoimmun Rev 3, 199-206.
36. Taiwo, Y.O., Bjerknes, L.K., Goetzl, E.J., Levine, J.D., (1989). Mediation of primary afferent peripheral hyperalgesia by the cAMP second messenger system. Neuroscience 32, 577-580.
37. Tarp, S., Bartels, E.M., Bliddal, H., Furst, D.E., Boers, M., Danneskiold-Samsoe, B., Rasmussen, M., Christensen, R., (2012). Effect of nonsteroidal antiinflammatory drugs on the C-reactive protein level in rheumatoid arthritis: A meta-analysis of randomized controlled trials. Arthritis Rheum 64, 3511-3521.
38. Tedesco, L.S., Fuseler, J., Grisham, M., Wolf, R., Roerig, S.C., (2002). Therapeutic administration of nitric oxide synthase inhibitors reverses hyperalgesia but not inflammation in a rat model of polyarthritis. Pain 95, 215-223.
39. Thakkar, H., Kumar Sharma, R., Murthy, R.S., (2007). Enhanced retention of celecoxib-loaded solid lipid nanoparticles after intra-articular administration. Drugs R D 8, 275-285.
40. Vossenaar, E.R., Zendman, A.J., van Venrooij, W.J., Pruijn, G.J., (2003). PAD, a growing family of citrullinating enzymes: Genes, features and involvement in disease. Bioessays 25, 1106-1118.
41. Wills, E.D., (1966). Mechanisms of lipid peroxide formation in animal tissues. Biochem J 99, 667-676.